

## RELEASE OF SHARES FROM VOLUNTARY ESCROW

Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, 'Aroa' or the 'Company') advises that, in accordance with ASX Listing Rule 3.10A and as stated in the Prospectus dated 22 June 2020 and the Annual Report dated 27 June 2022, 34,643,550 fully paid ordinary shares will be released from voluntary escrow on 23 July 2022. This represents 10.1% of the Company's issued share capital and is the final balance of the shares subject to voluntary escrow on ASX admission.

13,250,325 of the escrowed shares to be released were originally subject to a 36-month voluntary escrow period to 23 July 2023. The escrow terms provide for early release at 24-months if at any time after the Company's admission to the ASX the 5-day volume weighted average price of the shares reported on the ASX is 100% above the IPO offer price. This condition was satisfied in August 2020.

These shares are already quoted on ASX.

< ENDS >

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

## **About AROA™**

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. AROA's products have been used in more than four and a half million procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX:ARX). www.aroabio.com

## **Contacts**

Investor Relations Simon Hinsley **Investor Relations** shinsley@aroabio.com + 61 401 809 653

Media Australia Matthew Wright

matt@nwrcommunications.com.au +61 451 896 420

New Zealand Piet De Jong piet.dejong@baldwinboyle.com +64 21 812 766